Cited by 26HER2/EGFR in Cancer ResearchDigestive system and related healthGastric Cancer Management and Outcomes

Loss of Lrig1 Leads to Expansion of Brunner Glands Followed by Duodenal Adenomas with Gastric Metaplasia

Open access
Wang, Yang, Shi, Chanjuan, Lu, Yuanyuan, Poulin, Emily J., Franklin, Jeffery L., Coffey, Robert J.·2015·The American Journal of Pathology

Abstract

Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) is a pan-ErbB negative regulator and intestinal stem cell marker down-regulated in many malignancies. We previously reported that 14 of 16 Lrig1-CreERT2/CreERT2 (Lrig1(-/-)) mice developed duodenal adenomas, providing the first in vivo evidence that Lrig1 acts as a tumor suppressor. We extended this study to a larger cohort and found that 49 of 54 Lrig1(-/-) mice develop duodenal adenomas beginning at 3 months. Most adenomas were histologically low grade and overlaid expanded Brunner glands. There was morphologic and biochemical blurring of the boundary between the epithelium and Brunner glands with glandular coexpression of ErbB2, which is normally restricted to the epithelium, and the Brunner gland marker Mucin6. Some adenomas were high grade with reduced Brunner glands. At age 4 to 5 weeks, before adenoma formation, we observed enhanced proliferation in Brunner glands and, at 2 months, an increase in the size of the Brunner gland compartment. Elevated expression of the epidermal growth factor receptor (Egfr) ligands amphiregulin and β-cellulin, as well as Egfr and phosphorylated Egfr, was detected in adenomas compared with adjacent normal tissue. These adenomas expressed the gastric-specific genes gastrokine1 and mucin5ac, indicating gastric metaplasia. Moreover, we found that a subset of human duodenal tumors exhibited features of LRIG1(-/-) adenomas, including loss of LRIG1, gastric metaplasia (MUCIN5AC and MUCIN6), and increased amphiregulin and Egfr activity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajpath.2014.12.014

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Wang, Y., Shi, C., Lu, Y., Poulin, E. J., Franklin, J. L., & Coffey, R. J.
Affiliations
  • Vanderbilt University Medical Center (US)
  • Nashville VA Medical Center (US)
Corresponding author
Coffey, Robert J.
Venue
The American Journal of Pathology
Publisher
Elsevier BV
Published
2015-04
Volume
185
Issue
4
Pages
1123-1134
ISSN
0002-9440 (ISSN-L)
OpenAlex
W2113581487
Cited by
26
References
40
Citations by year
2025: 3 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 1 · 2019: 4 · 2018: 2 · 2017: 5 · 2016: 2
FWCI
1.31
Type
journal article
Language
en
Open access
Locations
  • American Journal Of Pathology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Vanderbilt University
  • Vanderbilt University Medical Center (P30DK058404)
  • National Institutes of Health
  • National Cancer Institute (CA151566, CA46413, R01CA151566, P50CA095103, R01CA046413)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK058404)
Topics
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Digestive system and related health
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Gastric Cancer Management and Outcomes
Keywords
Lrig1, duodenal adenoma, gastric metaplasia, Brunner glands, ERBB2, epidermal growth factor receptor, amphiregulin, tumor suppressor, intestinal stem cells, duodenal neoplasms
MeSH terms
Adenoma, Animals, Brunner Glands, Duodenal Neoplasms, Humans, Ligands, Membrane Glycoproteins, Metaplasia, Mice, Inbred C57BL, Models, Biological, Nerve Tissue Proteins, Stomach, Cell Proliferation, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review